c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth
factor, activates a wide range of different cellular signaling pathways, including those …

The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue
remodelling, which underlies developmental morphogenesis, wound repair, organ …

Organoid models have the potential to recapitulate the biological and pharmacotypic
features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis …

Cancer cells possess a broad spectrum of migration and invasion mechanisms. These
include both individual and collective cell-migration strategies. Cancer therapeutics that are …

Hepatocyte growth factor/scatter factor and its receptor, the tyrosine kinase Met, arose late in
evolution and are unique to vertebrates. In spite of this, Met uses molecules such as Gab1 …

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib,
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …

Metastasis follows the inappropriate activation of a genetic programme termed invasive
growth, which is a physiological process that occurs during embryonic development and …

The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth
factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular …

Ras-like GTPases are ubiquitously expressed, evolutionarily conserved molecular switches
that couple extracellular signals to various cellular responses. Rap1, the closest relative of …

Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic
molecularly targeted therapies. c-Met is a receptor tyrosine kinase shown to be over …